Assimon M, Pun P, Al-Khatib S, Brookhart M, Gaynes B, Winkelmayer W
Nephrol Dial Transplant. 2022; 37(11):2241-2252.
PMID: 35793567
PMC: 9585464.
DOI: 10.1093/ndt/gfac214.
Dietrichs E, Smith G
Front Med (Lausanne). 2022; 9:866454.
PMID: 35372426
PMC: 8966227.
DOI: 10.3389/fmed.2022.866454.
Su S, Sun J, Wang Y, Xu Y
Handb Exp Pharmacol. 2021; 267:139-166.
PMID: 33829343
DOI: 10.1007/164_2021_455.
Grotthus B, Szelag A
J Exp Pharmacol. 2020; 11:149-158.
PMID: 31920405
PMC: 6934109.
DOI: 10.2147/JEP.S209085.
Eugene A
PeerJ. 2019; 7:e7860.
PMID: 31616600
PMC: 6790106.
DOI: 10.7717/peerj.7860.
Psychotropic Drugs for the Management of Chronic Pain and Itch.
Belinskaia D, Belinskaia M, Barygin O, Vanchakova N, Shestakova N
Pharmaceuticals (Basel). 2019; 12(2).
PMID: 31238561
PMC: 6631469.
DOI: 10.3390/ph12020099.
Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
Assimon M, Brookhart M, Flythe J
J Am Soc Nephrol. 2019; 30(4):611-623.
PMID: 30885935
PMC: 6442344.
DOI: 10.1681/ASN.2018101032.
Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.
Giudicessi J, Ackerman M, Camilleri M
Neurogastroenterol Motil. 2018; 30(6):e13302.
PMID: 29441683
PMC: 6364982.
DOI: 10.1111/nmo.13302.
Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram.
Patel N, Wisniowska B, Jamei M, Polak S
AAPS J. 2017; 20(1):6.
PMID: 29181593
DOI: 10.1208/s12248-017-0155-8.
Citalopram and escitalopram: adverse cardiac outcomes in medically ill inpatients.
Elie D, Noohi S, Do A, Mahdanian A, Yu C, Segal M
Ther Adv Drug Saf. 2016; 7(5):225-226.
PMID: 27695624
PMC: 5014051.
DOI: 10.1177/2042098616660947.
The Effects of the Adenosine Receptor Antagonists on the Reverse of Cardiovascular Toxic Effects Induced by Citalopram In-Vivo Rat Model of Poisoning.
Buyukdeligoz M, Hocaoglu N, Oransay K, Tuncok Y, Kalkan S
Balkan Med J. 2015; 32(3):303-8.
PMID: 26185720
PMC: 4497698.
DOI: 10.5152/balkanmedj.2015.15932.
Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study.
Maljuric N, Noordam R, Aarts N, Niemeijer M, van den Berg M, Hofman A
Br J Clin Pharmacol. 2015; 80(4):698-705.
PMID: 25966843
PMC: 4594706.
DOI: 10.1111/bcp.12681.
Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.
Kogut C, Crouse E, Vieweg W, Hasnain M, Baranchuk A, Digby G
Ther Adv Drug Saf. 2014; 4(5):189-98.
PMID: 25114780
PMC: 4125314.
DOI: 10.1177/2042098613492366.
The role of adenosine receptors and endogenous adenosine in citalopram-induced cardiovascular toxicity.
Oransay K, Hocaoglu N, Buyukdeligoz M, Tuncok Y, Kalkan S
Indian J Pharmacol. 2014; 46(4):378-85.
PMID: 25097274
PMC: 4118529.
DOI: 10.4103/0253-7613.135948.
Escitalopram block of hERG potassium channels.
Chae Y, Jeon J, Lee H, Kim I, Choi J, Sung K
Naunyn Schmiedebergs Arch Pharmacol. 2013; 387(1):23-32.
PMID: 24045971
DOI: 10.1007/s00210-013-0911-y.
Citalopram and cardiac toxicity.
Cooke M, Waring W
Eur J Clin Pharmacol. 2012; 69(4):755-60.
PMID: 22996077
DOI: 10.1007/s00228-012-1408-1.
Prolonged QTc interval and torsades de pointes induced by citalopram.
Deshmukh A, Ulveling K, Alla V, Abuissa H, Airey K
Tex Heart Inst J. 2012; 39(1):68-70.
PMID: 22412232
PMC: 3298934.
Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.
Tan Y, Chen Y, You Q, Sun H, Li M
J Mol Model. 2011; 18(3):1023-36.
PMID: 21660488
DOI: 10.1007/s00894-011-1136-y.
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H
Naunyn Schmiedebergs Arch Pharmacol. 2010; 381(5):385-400.
PMID: 20229012
DOI: 10.1007/s00210-010-0496-7.
Open channel block of Kv1.5 currents by citalopram.
Lee H, Hahn S, Choi B
Acta Pharmacol Sin. 2010; 31(4):429-35.
PMID: 20228830
PMC: 4007671.
DOI: 10.1038/aps.2010.14.